|
Dear Seed Investor,
InMed Pharmaceuticals Inc. (CNSX:IN) (OTCMKTS:IMLFF) CEO Eric Adams recently sat down for two separate interviews regarding InMed's proprietary biosynthesis process, their patent filings and their research on using cannabinoids to treat various diseases.
InMed is one of the most exciting companies that we have come across, and both interviews are MUST LISTENS to get a good understanding on the company and their groundbreaking research.
From the Midas Letter:
InMed Pharmaceuticals Inc. (CNSX:IN) (OTCMKTS:IMLFF) (FRA:MWG2) performs research on extracted and purified cannabinoids to treat severe disease. President and CEO Eric Adams talks to James about the Canadian cannabinoid market, patenting, and their research on oils to treat a rare skin disorder often first seen on children.
LISTEN TO PODCAST AND READ THE TRANSCRIPT AT THE MIDAS LETTER
In addition to that interview, Mr. Adams also sat down with The Wall Street Analyzer for another in-depth interview:
LISTEN TO THE INTERVIEW AT THE WALL STREET ANALYZER
We highly recommend having a listen over the weekend.
High Profits,
The Seed Investor
|
|
|
|
